Truist analyst Asthika Goonewardene made no change to the firm’s Buy rating or $23 price target on Caribou Biosciences, telling investors in a research note that data in LBCL looks “solid.” The firm is optimistic that CB-010 can match autologous CAR-T like efficacy in an earlier line setting, but is “confused” with why the data in other histologies does not look as attractive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRBU:
- Caribou Biosciences 19.23M share Spot Secondary priced at $6.50
- Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
- Caribou: Follow-up data from Antler trial suggest CB-010 tolerated in r/r B-NHL
- Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
- Caribou Biosciences Announces Proposed Public Offering of Common Stock
